P Kanavos

Summary

Affiliation: London School of Economics
Country: UK

Publications

  1. ncbi request reprint Encouraging the use of generic medicines: implications for transition economies
    Derek R King
    LSE Health and Social Care, Room J404, Cowdray House, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, United Kingdom
    Croat Med J 43:462-9. 2002
  2. ncbi request reprint Do generics offer significant savings to the UK National Health Service?
    Panos Kanavos
    LSE Health, London School of Economics and Political Science, London, UK
    Curr Med Res Opin 23:105-16. 2007
  3. pmc Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?
    Andréa Dâmaso Bertoldi
    Postgraduate Program in Epidemiology, Federal University of Pelotas, Rua Marechal Deodoro 1160, 96020 220, Pelotas, Brazil
    Global Health 8:6. 2012
  4. pmc The less healthy urban population: income-related health inequality in China
    Wei Yang
    Department of Social Policy, LSE Health London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK
    BMC Public Health 12:804. 2012
  5. doi request reprint Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs
    Panos Kanavos
    Department of Social Policy, London School of Economics and Political Science, UK
    Health Aff (Millwood) 32:753-61. 2013
  6. doi request reprint What is wrong with orphan drug policies? Suggestions for ways forward
    Panos Kanavos
    Department of Social Policy and LSE Health, London School of Economics, London, UK
    Value Health 15:1182-4. 2012
  7. pmc The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors
    Fritz von der Schulenburg
    LSE Health London School of Economics, Houghton Street London WC2A, UK
    Health Econ Rev 1:18. 2011
  8. pmc Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP
    Panos Kanavos
    LSE Health, The London School of Economics and Political Science, London, UK
    Global Health 5:19. 2009
  9. ncbi request reprint A prospective view on European pharmaceutical research and development. Policy options to reduce fragmentation and increase competitiveness
    P Kanavos
    Department of Social Policy and Administration and LSE Health, London School of Economics and Political Science, England
    Pharmacoeconomics 13:181-90. 1998
  10. ncbi request reprint Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?
    Panos Kanavos
    LSE Health, London School of Economics and Political Science, UK
    Curr Med Res Opin 23:2467-76. 2007

Collaborators

Detail Information

Publications31

  1. ncbi request reprint Encouraging the use of generic medicines: implications for transition economies
    Derek R King
    LSE Health and Social Care, Room J404, Cowdray House, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, United Kingdom
    Croat Med J 43:462-9. 2002
    ..Quality of generic medicines is a pre-condition for all other measures discussed to take effect. The paper concludes by offering a list of policy options for decision-makers in Central and Eastern European economies in transition...
  2. ncbi request reprint Do generics offer significant savings to the UK National Health Service?
    Panos Kanavos
    LSE Health, London School of Economics and Political Science, London, UK
    Curr Med Res Opin 23:105-16. 2007
    ..The supply-side has been subject to price regulation, and the recent requirement for manufacturers/wholesalers to report prices net of discounts to the DoH, indicate that reimbursed prices for generics may be higher than commodity level...
  3. pmc Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?
    Andréa Dâmaso Bertoldi
    Postgraduate Program in Epidemiology, Federal University of Pelotas, Rua Marechal Deodoro 1160, 96020 220, Pelotas, Brazil
    Global Health 8:6. 2012
    ....
  4. pmc The less healthy urban population: income-related health inequality in China
    Wei Yang
    Department of Social Policy, LSE Health London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK
    BMC Public Health 12:804. 2012
    ..It is important to understand the variation in health across income groups, and in particular to take into account the effects of urban/rural residence on the degree of income-related health inequalities...
  5. doi request reprint Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs
    Panos Kanavos
    Department of Social Policy, London School of Economics and Political Science, UK
    Health Aff (Millwood) 32:753-61. 2013
    ..Similarly, US health care decision makers could consider requiring pharmaceutical manufacturers to provide more evidence about the value of new drugs in relation to the cost and negotiating prices accordingly...
  6. doi request reprint What is wrong with orphan drug policies? Suggestions for ways forward
    Panos Kanavos
    Department of Social Policy and LSE Health, London School of Economics, London, UK
    Value Health 15:1182-4. 2012
    ....
  7. pmc The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors
    Fritz von der Schulenburg
    LSE Health London School of Economics, Houghton Street London WC2A, UK
    Health Econ Rev 1:18. 2011
    ..Findings also indicate that, although originator prices are not immediately affected by generic entry, they may be influenced by changes in generic prices post patent expiry...
  8. pmc Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP
    Panos Kanavos
    LSE Health, The London School of Economics and Political Science, London, UK
    Global Health 5:19. 2009
    ..Overall, it sets a good example for access to treatment in developing countries, where such programmes can substitute or complement local efforts to provide care to eligible patients...
  9. ncbi request reprint A prospective view on European pharmaceutical research and development. Policy options to reduce fragmentation and increase competitiveness
    P Kanavos
    Department of Social Policy and Administration and LSE Health, London School of Economics and Political Science, England
    Pharmacoeconomics 13:181-90. 1998
    ....
  10. ncbi request reprint Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?
    Panos Kanavos
    LSE Health, London School of Economics and Political Science, UK
    Curr Med Res Opin 23:2467-76. 2007
    ..Generic manufacturers and wholesalers may offer discounts, rebates or promotions to pharmacies in order to gain an edge over their competitors, but their true extent is unknown...
  11. doi request reprint The dynamics of colorectal cancer management in 17 countries
    Panos Kanavos
    Department of Social Policy and LSE Health, London School of Economics, Houghton Street, London WC2A 2AE, UK
    Eur J Health Econ 10:S115-29. 2010
    ....
  12. doi request reprint Prescription drug coverage among elderly and disabled Americans: can Medicare-Part D reduce inequities in access?
    Panos Kanavos
    LSE Health, London School of Economics, Houghton Street, London, England
    Int J Health Care Finance Econ 10:203-18. 2010
    ..This continues to raise equity in access concerns among elderly patients...
  13. doi request reprint Determinants of branded prescription medicine prices in OECD countries
    Panos G Kanavos
    Department of Social Policy and LSE Health, London School of Economics, UK
    Health Econ Policy Law 6:337-67. 2011
    ..To the extent that remuneration of the distribution chain and taxation are directly and proportionately linked to product prices this is likely to persist over time...
  14. ncbi request reprint The economics of blood: gift of life or a commodity?
    Panos Kanavos
    LSE Health, London School of Economics, UK
    Int J Technol Assess Health Care 22:338-43. 2006
    ..To calculate the costs of blood collection, testing, storage, and transfusion in Greece...
  15. ncbi request reprint Health policy versus industrial policy in the pharmaceutical sector: the case of Canada
    M Vandergrift
    London School of Economics and Political Science, UK
    Health Policy 41:241-60. 1997
    ..The paper provides evidence from two such provinces, British Columbia and Ontario, and contrasts pharmaceutical policy-making at the provincial level with that at the federal level...
  16. ncbi request reprint Single European currency and Monetary Union. Macroeconomic implications for pharmaceutical spending
    P Kanavos
    Department of Social Policy and Administration and LSE Health, London School of Economics and Political Science, England
    Pharmacoeconomics 13:9-20. 1998
    ....
  17. ncbi request reprint Financing pharmaceuticals in transition economies
    P Kanavos
    LSE Health, London School of Economics, Houghton Street, London WC2A 2AE, England
    Croat Med J 40:244-59. 1999
    ..Policy-making needs to have a continuous long-term planning. The importation of policies into transition economy may require extensive and expensive adaptation, and/or lead to sub-optimal policy outcomes...
  18. ncbi request reprint Outstanding regulatory aspects in the European pharmaceutical market
    P Kanavos
    Department of Social Policy and LSE Health, London School of Economics and Political Science, England
    Pharmacoeconomics 15:519-33. 1999
    ..In addition, the definition of political expediency varies as one considers developments at the EU or national level, since it does not necessarily follow that individual actors coincide in opinion...
  19. ncbi request reprint The single market for pharmaceuticals in the European Union in light of European Court of Justice rulings
    P Kanavos
    London School of Economics and Political Science, London, UK
    Pharmacoeconomics 18:523-32. 2000
    ..The rulings add a further supranational dimension to a national policy issue and may have far reaching implications for the EU pharmaceutical market and industry...
  20. ncbi request reprint The rising burden of cancer in the developing world
    P Kanavos
    Department of Social Policy, London School of Economics, UK
    Ann Oncol 17:viii15-viii23. 2006
    ..Improved health care financing and international initiatives and/or partnerships could also provide additional impetus in targeting resources where needed urgently...
  21. ncbi request reprint Reference pricing for drugs: is it compatible with U.S. health care?
    Panos Kanavos
    Harvard Medical School, USA
    Health Aff (Millwood) 22:16-30. 2003
    ..This paper explores the difficult trade-offs that policymakers must make in designing such a system, drawing where relevant from experience abroad...
  22. ncbi request reprint Senior citizens and the burden of prescription drug outlays: what lessons for the Medicare prescription drug benefit?
    Panos Kanavos
    London School of Economics and Political Science, LSE Health, England
    Appl Health Econ Health Policy 3:217-27. 2004
    ..The study also finds evidence that women, those who are not married, middle income elderly and those in poor health, who purchase drugs more intensively, are at risk of incurring significant prescription OOP drug outlays...
  23. doi request reprint Colorectal cancer management in the United Kingdom: current practice and challenges
    Willemien Schurer
    LSE Health, London School of Economics, Houghton Street, London, WC2A 2AE, UK
    Eur J Health Econ 10:S85-90. 2010
    ..Overall, the focus on screening activities in the UK will hopefully result in fewer end-stage CRC cases and associated costlier treatments...
  24. ncbi request reprint [Constrained competition in parallel drug importation: the case of simvastatin in Germany, the Netherlands, and the United Kingdom]
    Joan Costa-Font
    London School of Economics and Political Science, United Kingdom Departament de Teoria Econòmica, Universitat de Barcelona, Barcelona, Espana
    Gac Sanit 21:53-9. 2007
    ..To examine the effects of parallel simvastatin importation on drug price in three of the main parallel importing countries in the European Union, namely the United Kingdom, Germany, and the Netherlands...
  25. doi request reprint Impact of regulation of Community Pharmacies on efficiency, access and equity. Evidence from the UK and Spain
    Maria Lluch
    LSE Health, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, UK
    Health Policy 95:245-54. 2010
    ..In sum, there are useful lessons for both countries: the UK could look into the policies applied in Spain that increase access and equity whilst Spain could adopt some of the policies from the UK to increase efficiency in the system...
  26. ncbi request reprint Economic issues in access to medications: schizophrenia treatment in England
    Martin Knapp
    TU Darmstadt, Institute for Material Science, Petersenstrasse 23, 64287 Darmstadt, Germany
    Int J Law Psychiatry 28:514-31. 2005
    ....
  27. doi request reprint Medical technology procurement in Europe: a cross-country comparison of current practice and policy
    Corinna Sorenson
    LSE Health, London School of Economics, Cowdray House, London, UK
    Health Policy 100:43-50. 2011
    ..More research is needed, however, to substantiate the role and influence of procurement on balancing the adoption and affordability of medical technologies...
  28. ncbi request reprint Will managed care work in Europe?
    E Mossialos
    LSE Health, London School of Economics and Political Science, England
    Pharmacoeconomics 11:297-305. 1997
    ..Finally, the policy-makers' dilemmas for resource allocation are examined and a frame-work for policy debate is suggested...
  29. ncbi request reprint Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom
    Steven G Morgan
    University of British Columbia
    Health Aff (Millwood) 25:337-47. 2006
    ..Rigor of process and transparency of data and rationale are believed to be important for maximizing the impact and political acceptability of the processes...
  30. ncbi request reprint Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study
    Sylvia Park
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA
    Br J Psychiatry 187:137-42. 2005
    ..The extent to which atypical antipsychotics have a lower incidence of extrapyramidal symptoms than typical antipsychotics has not been well-evaluated in community practice...
  31. ncbi request reprint Assessing the economic challenges posed by orphan drugs
    Michael F Drummond
    Centre for Health Economics, University of York, Heslington, York, UK
    Int J Technol Assess Health Care 23:36-42. 2007
    ....